Table 62Liraglutide compared with placebo: Summary of meta-analyses

Liraglutide dosageOutcomeNHeterogeneity
MeasureEstimate95% CIP valueI2P
0.6 mg to 0.65 mg dailyTotal WDs4aRR0.37(0.28; 0.50)<0.0010%0.720
WDs Due to AE4aRR0.70(0.23; 2.18)0.53738%0.185
1.2 mg to 1.25 mg dailyTotal WDs4bRR0.46(0.37; 0.58)<0.0010%0.759
WDs Due to AE4bRR1.69(0.51; 5.57)0.38771%0.016
1.8 mg to 1.9 mg dailyTotal WDs5cRR0.62(0.45; 0.85)0.00356%0.058
WDs Due to AE5cRR2.59(0.84; 7.95)0.09773%0.005
0.6 mg dailyHypoglycemia, minor3dRR1.28(0.55; 3.00)0.5630%0.660
Gastrointestinal2eRR1.76(1.16, 2.67)0.019619%0.266
1.2 mg dailyHypoglycemia, minor3fRR1.78(0.91; 3.47)0.09422%0.279
Gastrointestinal2gRR2.33(1.78; 3.04)<0.0010%0.980
1.8 mg dailyHypoglycemia, minor3hRR1.66(1.18; 2.34)0.0040%0.685
Gastrointestinal3iRR3.14(2.49; 3.94)<0.0010%0.808

Abbreviations: AE, adverse event; CI, confidence interval; RR, relative risk; WD, withdrawal.

a

Studies included in analysis: Vilsboll (2007), Seino (2008), Nauck (2009), Marre (2009).

b

Studies included in analysis: Vilsboll (2007), Nauck (2009), Zinman (2009), Marre (2009).

c

Studies included in analysis: Vilsboll (2007), Nauck (2009), Russell-Jones (2009), Zinman (2009), Marre (2009).

d

Studies included in analysis: Seino (2008), Nauck (2009), Marre (2009).

e

Studies included in analysis: Seino (2008), Nauck (2009).

f

Studies included in analysis: Nauck (2009), Zinman (2009), Marre (2009).

g

Studies included in analysis: Nauck (2009), Zinman (2009).

h

Studies included in analysis: Nauck (2009), Russell-Jones (2009), Zinman (2009), Marre (2009).

i

Studies included in analysis: Nauck (2009), Russell-Jones (2009), Zinman (2009), Marre (2009).

Studies included in analysis: Vilsboll (2007), Seino (2008), Nauck (2009), Marre (2009).

Studies included in analysis: Vilsboll (2007), Nauck (2009), Zinman (2009), Marre (2009).

Studies included in analysis: Vilsboll (2007), Nauck (2009), Russell-Jones (2009), Zinman (2009), Marre (2009).

Studies included in analysis: Seino (2008), Nauck (2009), Marre (2009).

Studies included in analysis: Seino (2008), Nauck (2009).

Studies included in analysis: Nauck (2009), Zinman (2009), Marre (2009).

Studies included in analysis: Nauck (2009), Zinman (2009).

Studies included in analysis: Nauck (2009), Russell-Jones (2009), Zinman (2009), Marre (2009).

Studies included in analysis: Nauck (2009), Russell-Jones (2009), Zinman (2009), Marre (2009).

From: Results

Cover of Drug Class Review: Newer Diabetes Medications, TZDs, and Combinations
Drug Class Review: Newer Diabetes Medications, TZDs, and Combinations: Final Original Report [Internet].
Jonas D, Van Scoyoc E, Gerrald K, et al.
Portland (OR): Oregon Health & Science University; 2011 Feb.
Copyright © 2011, Oregon Health & Science University.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.